Publication for CDH5 and VWF

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CDH5	cadherin 5	1003			[link]
hsa	VWF	von Willebrand factor	7450

Pubmed ID	Priority	Text
29233846	0.98	vWf TSSs showed a higher enrichment in H3K4me3, marker of TrxG activity and gene activation, in confluent VEC-positive cells than in VEC-null cells (Figure 2B, upper).
	0.98	vWf performed on endogenous Ezh2-bound chromatin immunoprecipitated from VEC-positive ECs treated with VEC-binding TAT-M6 and TAT-M10 peptides, beta-catenin-binding TAT-O4 and TAT-P30 peptides or nonbinding TAT-ctr-K11 peptide as control.
	0.98	VEC, we selected endothelial-specific claudin-5, VE-PTP, and vWf.
	0.97	vWf performed on endogenous Ezh (enhancer of zeste homolog)2-, Suz (suppressor of zeste)12-, Bmi1 (B lymphoma Mo-MLV insertion region 1)-, and H3K27me3 (histone H3 trimethylated on lysine 27)-bound chromatin immunoprecipitated from confluent VEC (vascular endothelial cadherin)-null and VEC-positive endothelial cells (ECs).
	0.97	VEC-null cells, beta-catenin/DNA interaction was abrogated, and Ezh2 binding to claudin-5, VE-PTP, and vWf promoters was strongly weakened (Figure 4B), suggesting a stabilizing role for beta-catenin on PcG protein association to target sites.
	0.96	VEC-positive cells with an adenovirus encoding a constitutively active form of FoxO1 (FKHR-TM [Forkhead transcription factor triple mutant]) significantly downregulated both VE-PTP and vWf expression (Online Figure IB).
	0.96	vWf performed on endogenous H3K4me3-bound and RNA polymerase II (p-PolII) Ser5-bound chromatin immunoprecipitated from confluent VEC-null and VEC-positive ECs.
	0.96	vWf expression in VEC-positive ECs treated with VEC-binding TAT-M10 peptide, beta-catenin-binding TAT-P30 peptide or nonbinding TAT-ctr-K11 peptide as control.
	0.95	vWf relies on VEC capacity to activate the PI3K/AKT pathway, leading to FoxO1 inactivation, and to sequester beta-catenin at the cell membrane.
	0.94	VEC-upregulated endothelial genes, we selected the tyrosine phosphatase VE-PTP and the extracellular matrix protein vWf for further studies.
	0.93	vWf, T-cell lymphoma invasion and metastasis-1 (Tiam1), LIM domain only-2 (Lmo2), signal transducer and activator of transcription-6 (Stat6) and Elk3 (ETS domain containing protein) among VEC-induced genes, hes-related family bHLH transcription factor with YRPW motif-1 (Hey1) and adrenomedullin (Adm) among VEC-repressed genes, and platelet/endothelial cell adhesion molecule-1 (Pecam1) and SRY (sex determining region Y)-box-18 (Sox18) as genes not influenced by VEC expression (Online Figures IA and IIA through IIC).
	0.91	vWf performed on endogenous Ezh2-bound chromatin immunoprecipitated from confluent VEC-positive and VEC-null ECs expressing dominant negative form of Tcf4 (TCF4-DN) or GFP (green fluorescent protein; negative control).
	0.87	VEC Interaction Downregulates Claudin-5, VE-PTP, and vWf Expression
	0.86	vWf, we aimed at inhibiting Ezh2/VEC and Ezh2/beta-catenin interactions.
	0.59	vWf expression in confluent VEC-null and VEC-positive ECs upon Suz12 overexpression.
19587802	0.98	vWF (blue bar) and VE Cadherin (purple bar).
	0.97	vWF and VE cadherin when compared with CD31 (see table 3).
	0.95	vWF and VE cadherin staining in the endothelium of biopsies by using method 3 (defined in materials and methods) comparing the photomicrographs of serial section for vessels which were positive for CD31 but negative for either of the other two antibodies.
	0.93	vWF and VE cadherin compared with the same biopsies stained with CD31 (Table 3).
	0.80	vWF and VE cadherin was 17.8+-3, 18.1+-3, and 18.3+-4, respectively.
	0.76	vWF 14.6+-3 and for VE cadherin 16.2+-3.
25711526	0.98	vWF and VE-cadherin proteins.
	0.96	vWF and VE-cadherin proteins (Figure 5I), which are considered highly specific to endothelial populations.
	0.96	vWF and VE-cadherin.
	0.95	vWF and VE-cadherin was once again similar (Figure 5C & D, L-N).
	0.72	vWF and VE-cadherin protein were normalized to sampleappropriate beta-actin signal in M and N, respectively.
	0.57	vWF and VE-cadherin levels to values that were not significantly different than cells cultured in PEGylated fibrin.
28859673	0.98	VE-cadherin, vWF, eNOS, CD34, CD133 as shown in Table 2.
	0.96	VE-cadherin, CD31, vWF, CD45- while the HUVEC derived EPC markers are CD133, P1H12, VEGFR2, PECAM, and endoglin, ICAM1.
	0.93	VE-cadherin, vWF.
	0.61	VE-cadherin, Flt-1, KDR, e-NOS, vWF while early EPC has a weak expression level of VE cadherin and KDR.
	0.51	von Willebrand factor (vWF), vascular endothelial cadherin (VE-Cadherin), endothelial nitric oxide synthase (eNOS), uptake of DiI AcLDL and BS-1 or UEA-1 lectin binding.
29670017	0.98	CD144, and vWF positive GSCs after 24 h under hypoxic conditions (Figure 3B,C).
	0.96	CD144, and vWF) and VEGF secretion.
	0.95	CD144, and vWF positive cells (Figure 3B,D), and an almost total decrease in VEGF secretion (Figure 3E) in GSCsA3-KO under hypoxia.
	0.87	CD144, and vWF positive cell population, suggesting that the expression of these markers depends on AR activation; probably due to increased adenosine production in GSCs under hypoxic conditions.
	0.60	CD144, CD31, and vWF and VEGF secretion are regulated by adenosine and A3AR activation.
25418725	0.98	CD144, but did not express vWF or intercellular adhesion molecule 1 (ICAM-1) (Figure 6).
	0.97	CD144, vWF, ICAM-1, and KDR, but did not express CD117, CD34, or TIE-2 (Figure 6).
	0.97	vWF+CD144+ endothelial cells were capable of approximately 20 population doublings over 2 months, generating more than 1 million cells from a single endothelial cell (Figure 7A).
	0.97	VE-cadherin+vWF+CD34- endothelial cells were expanded for 20 doublings over 2 months and maintained expression of endothelial cell markers (CD31+VE-cadherin+CD34-).
25371856	0.98	CD144 and CD31/vWF of endothelialized psoriatic or healthy substitutes.
	0.97	CD144- and vWF-positive CLSs are red, and the nuclei of cells are blue (white arrows indicate CLSs; scale bar=50 mum).
	0.75	CD144 (first set of figures) and CD31-vWf (second set of figures) in endothelialized psoriatic or healthy substitutes (scale bar=100 mum).
28457188	0.98	VE-CADHERIN, VWF, and LECTIN (Fig. 1A-D).
	0.98	VE-CADHERIN, PECAM1, VWF, alpha-SMA, and LAMININ (Fig. 2A-F).
	0.87	VE-CADHERIN (C, D), LECTIN (B, D), and VWF (A, C).
28839272	0.98	VE-cadherin, anti-PECAM-1 and anti-vWF antibodies.
	0.96	VE-cadherin, KDR and vWF (EC markers), whereas nearly 100% of ECpa were positive for PECAM-1, VE-cadherin, KDR and vWF.
	0.91	VE-cadherin, PECAM-1 and vWF while iPSC were negative for these markers (Fig. 2a).
25070152	0.98	vascular endothelial (VE)-cadherin (CD144), endothelial nitric oxide synthase (eNOS), von Willebrand Factor (vWF), vascular endothelial growth factor receptor-2 (VEGFR2), and Tie-2.
	0.91	VE-cadherin, CD31, vWF, Tie2 and VEGFR-2.
28101109	0.98	vWF and CD39 and VE-cadherin+ cobble-stone structures formation observed during differentiation of CEDPs indicate maturation of endothelial cells (Figures 5(g)-5(i)).
	0.97	vWF and CD39 in VE-cadherin+ endothelial cells after 10 days of CEDPs differentiation.
20509943	0.98	vWF, VE-cadherin, and Tie1.
28362648	0.98	VWD BOEC, T1-3 was stained for VE-Cadherin (red) and DAPI (blue).
29569797	0.98	CD144, eNOS, and vWF).
22605545	0.97	vWF (90%), VE-Cadherin (60%) and PECAM-1 (48%) positive cells, than in EBM.
	0.97	vWF, VE-Cadherin, CD31, eNOS and Flk-1 by day 10.
	0.96	von Willebrand factor, a multimeric glycoprotein, synthesized in ECs and stored in the Weibel-Palade bodies; CD31 (PECAM-1), a glycoprotein expressed by ECs at the endothelial cell junction, and VE-cadherin, which is specifically localized to the inter-endothelial cell junction.
	0.94	vWF (A), VE-Cadherin (D) and PECAM-1 (G).
	0.93	VE-Cadherin, and vWF with an increase in the VEGF dosage which reached a plateau beyond 50ng/ml.
	0.92	vWF, ability to take up acetylated LDL, in vitro angiogenesis assay, flow cytometry and qPCR of EC markers vWF, VE-cadherin, PECAM-1, CD34, VEGF-R1 and VEGF-R2 after 10days of stimulation.
	0.91	vWF (87+-3%) (Fig. 5B), VE-Cadherin (24+-5%) (Fig. 5E), and PECAM-1(18+-3%) (Fig. 5H).
	0.85	vWF expression in the differentiating cells in EGM and EGM+VEGF media, when compared to the other markers, VE-Cadherin and PECAM-1, might be due to the fact that vWF is expression is initiated even in the premature ECs, whereas VE-Cadherin and PECAM-1 are expressed in mature ECs.
	0.80	vWF (C), VE-Cadherin (F) and PECAM-1 (I).
	0.68	vWF, VEGF-R1 and R2, VE-cadherin and VCAM-1 when stimulated using medium containing 50ng/ml VEGF and 2%FBS, after 7days of stimulation.
	0.68	vWF, (B) PECAM-1, (C)VE-Cadherin, (D) VEGF-R1 and (E) VEGF-R2 in cells cultured in EBM, EGM and EGM+VEGF for 10days. (***p<0.001, **p<0.01 and *p<0.05).
	0.62	vWF, VE-Cadherin and PECAM-1.
	0.57	vWF (B), VE-Cadherin (E) and PECAM-1 (H).
19875721	0.97	VE-Cadherin, von Willebrand Factor (vWF), CD45, and beta-actin expression (Figure 1A and Supplemental Figure I A; for supplemental figures, please see http://atvb.ahajournals.org).
	0.97	VE-Cadherin expression, a small amount of vWF expression, and no CD45 expression.
	0.97	VE-Cadherin, and vWF, but still had no CD45 expression.
	0.97	VE-Cadherin, vWF, and CD45 revealed that increasing the VEGF dose to 50 ng/ml had a positive effect on the expression of CD31, VE-Cadherin, and vWF, and that this effect reached a plateau beyond 50 ng/ml (Figure 1B).
	0.96	VE-Cadherin, and von Willebrand Factor, but not the hematopoietic cell marker CD45.
	0.96	vWF expression but low levels of CD31 and VE Cadherin expression.
	0.96	VE-Cadherin, and vWF at all time points from day 4 of differentiation onwards.
	0.91	VE-Cadherin or vWF expression, and no CD45 expression.
	0.86	VE-Cadherin, vWF, and CD45 (Figure 1C).
	0.69	VE-Cadherin, and vWF protein than standard EBs or OP9 coculture.
24373581	0.97	vWF, VE-cadherin and VEGFR2.
	0.95	vWF, VE-cadherin and VEGFR2 by human dermal microvascular endothelial cells (HDMEC) monocultures and cHDMEC (the endothelial cell population sorted from the co-culture), in the absence (control) and in the presence of Alendronate (AL) and Zoledronate (ZL), 10-12 and 10-6 M. Asterisks (*) significantly different from control (absence of AL or ZL), P <= 0.05.
	0.95	vWF and VE-cadherin by cHDMEC, and increased expression of ALP, BMP-2 and OC by cHMSC, an effect that was not seen in the respective monocultures.
	0.89	vWF and VE-cadherin are not available.
26599408	0.97	VE-cadherin did stain for vWf, either with or without WPB.
	0.94	vWf together with either CD31 or VE-cadherin validates vWf staining.
	0.92	vWf positive cells also stained for CD31 or VE-cadherin at P0 and P2 and in IEC and AEC.
	0.90	vWf staining as a reliable EC marker despite its multiple patterns of presentation, confluent IECs and AECs, at P0 or P2 stages, were stained for other EC markers such as CD31 or VE-cadherin (Fig 2C).
16430777	0.97	von Willebrand factor (factor-8 or vWF), PE-CAM, VE-Cadherin, VEGF-receptors.
	0.94	von Willebrand factor (factor 8, or vWF) and VE-cadherin.
	0.60	VE-cadherin, PECAM-1 and vWF as an indicator of degree of angiogenesis in breast cancer, as we previously reported.
30846769	0.97	VE-cadherin and vWF (Fig. 2d).
	0.95	VE-cadherin, vWF) as well as EC specification markers (COUP-TFII and Ephrin B2) by immunofluorescence.
	0.93	VE-cadherin and vWF (Fig. 1d).
31265169	0.97	VWF in Weibel-Palade bodies.3 To investigate whether the ECFC lines were able to store VWF in Weibel-Palade bodies, all ECFC lines were stained for VWF and endothelial marker VE-cadherin.
	0.95	VWF in Weibel-Palade bodies more at the periphery of the cell in lines with a high maximum cell density (ECFC 4B), VWF in elongated Weibel-Palade bodies dispersed throughout the whole cell in lines with an intermediate maximum cell density (ECFC 5E), and sparse VWF and more diffuse VE-cadherin staining in lines with a low maximum cell density (ECFC 6B).
	0.83	VWF (green) and VE-cadherin (red).
19379144	0.97	vWF, CD146 and CD144.
	0.84	von Willebrand factor [vWF], CD31, CD144) but are negative for leucocyte markers.
30360780	0.97	CD144; VE-cadherin, CD105; endoglin, CD54; ICAM-1, vWF; von Willebrand factor, ACE; angiotensin converting enzyme, TF; tissue factor, PS; phosphatidylserine, TSG101; tumor susceptibility gene 101 protein, CD9, CD63, CD81, CD82; tetraspanins.
	0.75	CD144, CD105, CD54, and vWF.
31142801	0.97	vWF was markedly expressed with a punctuate pattern in the cytoplasm of CD144-positive cells (Fig. 1f).
	0.64	CD144 and vWF staining.
32154424	0.97	CDH5, CD34, KDR, and vWF in purified iEPCs on day 8 derived from three hiPS cell lines and HUVECs.
	0.81	CDH5, CD34, KDR, vWF, and MMP1 of iEPCs derived from two different iPS cell lines and HUVECs.
24707174	0.97	vascular endothelial-cadherin; platelet endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin; CD51; CD105; von Willebrand factor; and CD143 EMPs.
29170757	0.97	vWF and VE-cadherin expression by immunostaining (d).
32210018	0.97	vWF, and VE-cadherin in the vECs on both FN and FN + DCN coating (Figure 7c).
24341512	0.96	vWF and VE-cadherin).
	0.95	VE-cadherin, vWF and in particular the VEGF-R1 (flt-1) transcripts were more strongly expressed in CD34+ cells cultivated in the presence of PT45-CM, versus controls (p = 0.03, p = 0.03 and p = 0.02, respectively).
	0.95	vWF and VE-cadherin.
	0.95	VE-cadherin and vWF, and a subset of cells started to express VEGF-R1 RNAm.
	0.62	VE-cadherin, vWF, VEGF-R1 and VEGF-R2 mRNA in CD34+ cultured with or without PT45-CM.
	0.58	VE-cadherin and vWF in CD34+ cells cultured with or without PT45-CM.
28003219	0.96	CDH5 and KDR (upper panel), and VWF and PECAM1 (lower panel) in transduced HDFs at D7.
	0.91	CDH5, KDR, PECAM1, CD34, and TEK, but not VWF, were markedly increased compared to the uninfected HDFs (Online Figure IC).
	0.84	CDH5, KDR, VWF and PECAM1 (Figure 3D and Online Figure VII).
	0.82	CDH5, KDR, PECAM1, and VWF.
	0.73	CDH5, KDR and TEK but lower expression of PECAM1 and VWF, which are known markers of mature ECs.
30008231	0.96	VE-cadherin (EC marker), red is phalloidin (cytoskeletal marker) and yellow is vWF (EC marker).
	0.94	vWF and VE-cadherin expressed by the HUVECs cultured on HB scaffolds (Fig. 9).
	0.85	VE-cadherin or vWF) and with phalloidin, indicating the presence of ECs on the fiber bridging structure.
	0.85	vWF, CD31, and VE-cadherin) between hSMC/EC co-culture and HUVECs monoculture on HB scaffolds (Fig. 10A).
	0.74	vWF (1.5-4.6-fold increase); CD31 (2.5-7.1-fold increase); and VE-cadherin (1.7-5.1-fold increase).
18599796	0.96	vWF, another EC maturation marker, VE-cadherin, and ICAM-1 increased in a dose-dependent manner.
	0.87	VE-Cadherin (VE-Cad), vWF and ICAM-1.
	0.78	VE-cadherin, vWF, and ICAM-1, which are markers for ECs but not EPCs.
24485793	0.96	CD144, and vWF-8 mRNA were more than 1000-fold greater in purified hiPSC-ECs than in undifferentiated hiPSCs (Figure 4C).
	0.92	CD144, and vWF-8 mRNA were normalized to GAPDH, and presented as fold changes.
	0.66	CD144, and vWF-8 at week-1 (D1, E1, and F1) and week-4 (D2, E2, and F2) after isolation were evaluated via immunofluorescence; nuclei were counterstained with DAPI.
19715692	0.96	VE-cadherin, vWF and Tie2 in response to DNMT inhibition in ESC
	0.66	Vwf (B), VE-cadherin (C), Tie-2 (D), and the angiogenic gene Angiopoietin-1 (E), was determined by quantitative real time PCR.
26417289	0.96	cdh5 in MSCs and further culture of these CD34 cells induced them to express vWF and Pecam1.
	0.75	vWF, Pecam1 and Cdh5 (Figure 1(Fig. 1))).
31649666	0.96	VE-cadherin, von Willebrand factor (VWF), and Akt phosphorylation in response to aGVHD sera.
25093183	0.95	VE-cadherin (a, in green), Tie2 (b, in red), vWF (c, in green), and CD34 (d, in green) colabelled nascent vessels.
	0.72	VE-cadherin, CD34, and Tie-2 or for vWF, a later vascular marker (Figure 9).
	0.55	VE-cadherin on its basal side (Figures 7(a) and 7(b) and Figure 9(a), arrows) and also for VEGF-R2 (Figures 7(c) and 7(d), arrows) but not for CD31 (Figure 8(a)), CD34 (Figure 9(d)), Tie-2 (Figure 8(c)), or vWF (Figure 8(b)).
30892142	0.95	VWF, CDH5, ICAM2, SOX17, DLL4, as well as ERG itself (Figure 2A and 2B).
	0.68	CDH5 (VE-cadherin), DLL4 (Delta-like protein 4), CLDN5 (claudin-5), and VWF (von Willebrand factor) and controls processes including survival, permeability, and cytoskeletal dynamics (reviewed in Shah et al).
23079999	0.95	VE-Cadherin (B), eNOS (C), and vWF (D) in ECs derived from pluripotent stem cells at day 21 of differentiation protocol.
23520160	0.95	VE, Tie-1, and vWF, were significantly up-regulated in the iEnd cells as compared to fibroblasts (Figure 2D).
24018375	0.94	CD144, eNOS, VEGFR1/2/3 and vWF).
	0.94	CD144, vWF, VEGF-A receptor 1 (Flt1) or 2 (KDR), or neurofilament (scale bars = 50 mum and 10 mum).
	0.86	CD144/vWF.
	0.84	CD144+ or Isl1+vWF+, were identified in the outflow tract (OFT) region of human fetal hearts at gestation week 9.
	0.76	CD144 or vWF (Figure 1A).
	0.66	CD144+ or Isl1+vWF+) in OFT region of the early human fetal hearts (gestation week 9), in addition to the previously reported human Isl1-expressing smooth muscle and cardiac myocyte intermediates.
28972000	0.94	VWF in the CDH5+ cell fraction (shown is an example of H9).
	0.88	CDH5, and VWF (Figure 1C and Supplemental Figure 3B) and decreases in PTPRC (CD45), CD34, KIT (CD117), and PROM1 (CD133) (Supplemental Figure 4A-C).
	0.69	CDH5, and VWF at day 14 compared to undifferentiated hPSCs and mesodermally-differentiated hPSCs at day 3.
	0.69	CDH5+ cells exhibited 3- to 8-fold higher mRNA expression of KDR, NOS3 (eNOS), and VWF compared to CDH5- cells (Figure 1E).
	0.67	CDH5+ cells expressed VWF, 79.0% TEK, and 66.3% KDR, suggesting substantial enrichment of the EC population in the CDH5+ cell fraction (Figure 1D).
	0.64	CDH5 and VWF expression (Supplemental Figure 3A).
30327649	0.93	VWF with PECAM1 (left) and CDH5 (right) in both HC (black dots) and SSc (red dots) skin cells.
	0.66	VWF against PECAM1 and CDH5 demonstrated that the cells expressing high levels of VWF were also the cells that expressed increased levels of PECAM1 and CDH5 (Figure 1C).
	0.60	VWF, CDH5, PECAM1, and GAPDH genes in the cells derived from HC and SSc skin.
	0.60	VWF, PECAM1, and CDH5 for each cell.
19796498	0.93	vWF, CD31, VE-cadherin, Flk-1 and Flt-1 was significantly increased in cell-cell contact co-culture (direct), but not in transwell co-culture (indirect) group; B. Western blot analysis showed that protein expression of endothelial specific markers (vWF and CD31) was upregulated in direct cell-cell contact culture, but not in transwell co-culture system; C. Normalization of protein expression by beta-actin.
	0.86	vWF, CD31, VE-cadherin, and Flk-1 were significantly increased by TACE.
22652782	0.93	von Willebrand factor (vWF), CD31, and CD144 are actually mature EC markers, whereas another potential EPC marker C-X-C chemokine receptor type 4 (CXCR4) is expressed on numerous cell types.
25563650	0.91	von Willebrand factor (vWF), and vascular endothelial cadherin (VE-cadherin) (A).
	0.89	VE-cadherin, vascular endothelial cadherin; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
18197262	0.91	VE cadherin (p = 0.008), and von Willebrand factor (p = 0.033) (Table 1 Section A).
27236750	0.90	VWF (1:1000, green) and VE-cadherin as endothelial cell marker (1:200, red) revealed partial expression of VWF in GECs.
31942548	0.89	vascular endothelial (VE-) cadherin and VWF, and have been used in functional studies (Fig. 3).
	0.81	VWF (green stain) and VE-cadherin (red stain) in immunofluorescent staining, blue stain for nuclei (DAPI).
29067104	0.88	vascular endothelial cadherin, cluster of differentiation (CD)31, CD34, epidermal growth factor homology domains-2, von Willebrand factor and endothelial nitric oxide synthase was assessed by reverse transcription-polymerase chain reaction.
	0.83	VE-cadherin, CD31, CD34, Tie-2, vWF and ec-NOS.
29785538	0.88	VE-cadherin and rise of vWF marker expression in case of higher negative stress phase angles.
	0.75	vWF (b) and VE-cadherin (c) in ASCs, exposed to SPA = 0, - 45 and - 90 .
29884885	0.88	von Willebrand factor (VWF), vascular endothelial growth factor receptror-1 (VEGFR-1) and VE-Cadherin, thus confirming their endothelial phenotype (Fig. 1A).
	0.54	VWF (green fluorescent labelling), VEGFR-1(red fluorescent labelling) and VE-Cadherin(red fluorescent labelling) was performed on cultured ECs.
21212411	0.88	CD144 and VWF in 40.4% +- 5.5% and 53.7% +- 4.3% of VEGFR-1-expressing ABCB5+ melanoma cells, respectively (mean +- SE, n = 6) compared with minimal or absent induction in ABCB5- melanoma cells with low to negative VEGFR-1 expression (P < 0.0001) (Fig. 2A).
19109954	0.86	vWf (2.4-fold control; Figure 1E) and VE-cadherin (2.2-fold control; Figure 1F) levels increased significantly within 2 weeks after CBDL, a time frame similar to that seen for microvessel changes by FVIII staining and microvessel counting.
29377939	0.85	von Willebrand factor (vWf), soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM) and soluble vascular endothelial cadherin (sVE-cadherin) in the blood of women affected by CVI.
	0.63	von Willebrand factor (vWf), soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM) and soluble VE-cadherin (sVE-cadherin) in CVI women who constitute the most numerous group of patients suffering from venous disease.
31624792	0.85	VE-cadherin (CD144; Figure 3) and platelet EC adhesion molecule-1 (CD31; Figure S2) at cell-cell junctions with no obvious differences between VWF -/- and CTRL clones.
28249049	0.82	VWF and VE-cadherin (S2 Fig) or PECAM (S2 Fig).
28901188	0.79	VE-cadherin, vWF, eNOS, and some Ephrin type-B receptor 4 (EphB4) positivity (Fig. 4A to E).
26500761	0.73	vWF, CD31, VE-cadherin, angiopoietin-related protein 4, and CD34) were upregulated.
	0.52	vascular endothelial:cadherin (VE-cadherin), von Willebrand factor (vWF), vascular endothelial growth factor receptor 2 (VEGFR-2), thrombomodulin, and endoglin.
30240741	0.73	CD144 (vascular endothelial [VE] cadherin), a major endothelial adhesion molecule; and von Willebrand factor (vWF), a glycoprotein that mediates platelet adhesion in the endothelium (Figure 1A).
	0.64	CD144 (i) and vWF (ii) with merged (iii) and zoomed (iv) views, and (v) CD31 and vWF.
19847290	0.68	VE-cadherin, VEGFR-1, VEGFR-2, vWF, and CD105, and assayed by flow cytometry (Fig. 2).
20046878	0.62	CD144 are expressed on cell membranes, and vWF in the cytoplasm.
32010293	0.61	vWF and CD144 on day 21, compared with cells seeded on CG scaffold.
21420373	0.58	vWF, VE-cadherin, PECAM-1, and VEGFR2), in comparison, HBMSCs cultured at high density produced more abundant EC marker expression, formed more robust tubules (Fig. 7B), and were found to induce significantly larger blood vessels in the CAM (Fig. 7C).
	0.54	VE-cadherin, PECAM-1, and vWF.
28323620	0.52	Cdh5 and Vwf in heterokaryons consisting of human iPSC (hiPSC) and murine EC (mEC) compared to Co-culture control.
22591741	0.51	vWF (Figure 6 E, F), CD144 (Figure 6 K, L), CD146 (data not shown) and eNOS (Figure 6 M, N) with no evident difference in fluorescence intensity between HUVEC from the control group and group A. Presence of CD31 and vWF was also detected in endothelium of the human umbilical vein (figure C, D and G, H).